AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31529385 — intervention group
Group type: EXPERIMENTAL
Intervention: TM alone
Number of subjects: 56
Study 31529385 — intervention group
Group type: COMPARATOR
Intervention: CR alone
Number of subjects: 56
Study 31529385 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study 31529385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TM group
Number of subjects: 56
Study 31529385 — intervention group
Group type: COMPARATOR
Intervention: Combined non-TM group
Number of subjects: 56
Study 30908813 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS ON
Number of subjects: 16
Study 30908813 — intervention group
Group type: COMPARATOR
Intervention: STN-DBS OFF
Number of subjects: 16
Study 29554516 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional rehabilitation (EFR)
Number of subjects: 14
Study 29554516 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR)
Number of subjects: 14
Study 29554516 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (EFR and CR)
Number of subjects: 14
Study 26829661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF)
Number of subjects: 1733
Study 26829661 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate (TDF)
Number of subjects: 1733
Study 25103026 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal TDCS (2 mA, 30 min) applied to the cerebellum during PASvar360p (360 electrical stimuli of the right median nerve paired with TMS at ISIs of 25 ms and 21.5 ms)
Number of subjects: 24
Study 25103026 — intervention group
Group type: COMPARATOR
Intervention: Sham TDCS applied to the cerebellum during PASvar360p
Number of subjects: 24
Study 21997545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with colonoscopy screening
Number of subjects: 100000
Study 21997545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with sigmoidoscopy screening
Number of subjects: 100000
Study 21997545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 100000
Study 21997545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin with colonoscopy and sigmoidoscopy
Number of subjects: 100000
Study 21997545 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased proximal CRC prevention rate with colonoscopy
Number of subjects: 100000
Study 21997545 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic analysis
Number of subjects: 100000
Study 20439824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy
Number of subjects: 53
Study 20439824 — intervention group
Group type: COMPARATOR
Intervention: Enriched supportive therapy
Number of subjects: 53
Study 18078406 — intervention group
Group type: EXPERIMENTAL
Intervention: Undershirts coated with borage oil (for 2 weeks)
Number of subjects: 32
Study 18078406 — intervention group
Group type: COMPARATOR
Intervention: Non-coated undershirts (placebo)
Number of subjects: 32
Study 16234012 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mug IFN-gamma intramuscularly daily for 3 months and on alternate days for the subsequent 6 months
Number of subjects: 99
Study 16234012 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 99
Study 16234012 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma group
Number of subjects: 99
Study 16234012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 12399271 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g almonds/d for 4 wk
Number of subjects: 50
Study 12399271 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-almond diet (HFA)
Number of subjects: 50
Study 12399271 — intervention group
Group type: COMPARATOR
Intervention: High-fat control diet (HFC)
Number of subjects: 50
Study 12399271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-almond diet (LFA)
Number of subjects: 50
Study 12399271 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet (LFC)
Number of subjects: 50
Study 12399271 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond diets
Number of subjects: 50
Study 10196648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pseudoephedrine (60 mg capsule)
Number of subjects: 54
Study 10196648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8561098 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 37
Study 8561098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 2177062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10, 20, and 40 mg once-daily)
Number of subjects: 70
Study 2177062 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25, 50, and 100 mg twice-daily)
Number of subjects: 70
Study 389483 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH) therapy for 2 years
Number of subjects: 36
Study 389483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DPH therapy)
Number of subjects: 36
Study 30238239 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stage periarticular injection (just prior to arthrotomy)
Number of subjects: 105
Study 30238239 — intervention group
Group type: COMPARATOR
Intervention: Late stage periarticular injection (after implanting the prosthesis)
Number of subjects: 105
Study 25439631 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 30
Study 25439631 — intervention group
Group type: COMPARATOR
Intervention: Modified nociceptive trigeminal inhibition splint
Number of subjects: 30
Study 23820052 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (MST)
Number of subjects: 7
Study 23820052 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 7
Study 21459271 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin for median duration of 28 months
Number of subjects: 0
Study 21459271 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 19632099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (n=22)
Number of subjects: 199
Study 19632099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (n=26)
Number of subjects: 199
Study 19632099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study 17565514 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine (Group L)
Number of subjects: 45
Study 17565514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (Group R)
Number of subjects: 45
Study 17565514 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 45
Study 15581045 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-gemcitabine-trastuzumab (TGH) regimen: paclitaxel 80 mg/m2/week, gemcitabine 1000 mg/m2 every 2 weeks, trastuzumab 4 mg/kg loading dose then 2 mg/kg/week for 12 weeks
Number of subjects: 40
Study 15581045 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity assessment
Number of subjects: 40
Study 11377362 — intervention group
Group type: EXPERIMENTAL
Intervention: New computer algorithm for real-time quantification of electrocardiographic differences
Number of subjects: 0
Study 9693894 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural bupivacaine blockade (n = 43)
Number of subjects: 90
Study 9693894 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (control group)
Number of subjects: 90
Study 8164030 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (100 U/kg body weight subcutaneously) three times per week
Number of subjects: 100
Study 8164030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 100
Study 3221746 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxicam 20 mg/day for 20 days
Number of subjects: 0
Study 3221746 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day for 20 days
Number of subjects: 0
Study 29941861 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine HCl with epinephrine (LL group)
Number of subjects: 381
Study 29941861 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine spray (TL group)
Number of subjects: 381
Study 29941861 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/h lidocaine infusion (GL group)
Number of subjects: 381
Study 29017479 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK) performed in groups during working hours for 10 min 5 days per week
Number of subjects: 200
Study 29017479 — intervention group
Group type: COMPARATOR
Intervention: Home-based physical exercise (HOME) performed alone during leisure time for 10 min 5 days per week
Number of subjects: 200
Study 26300237 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction intervention followed by diet and exercise counselling over 32 months
Number of subjects: 67
Study 23163416 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion group (intervention)
Number of subjects: 0
Study 23163416 — intervention group
Group type: COMPARATOR
Intervention: Nondepletion control group (control)
Number of subjects: 0
Study 21569186 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick-release bromocriptine
Number of subjects: 0
Study 21569186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18285535 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3,000 mg/day
Number of subjects: 120
Study 18285535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16569746 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (younger than 65 years)
Number of subjects: 70
Study 16569746 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (younger than 65 years)
Number of subjects: 70
Study 16569746 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (65 years and older)
Number of subjects: 70
Study 16569746 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (65 years and older)
Number of subjects: 70
Study 16569746 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (both age groups)
Number of subjects: 70
Study 16569746 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (both age groups)
Number of subjects: 70
Study 15290665 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (750 microg; n = 351)
Number of subjects: 1127
Study 15290665 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesylate (500 mg; n = 381)
Number of subjects: 1127
Study 15290665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline; n = 395)
Number of subjects: 1127
Study 11763977 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg q.i.d. after 200 microg intravaginal misoprostol for 5 days)
Number of subjects: 80
Study 11763977 — intervention group
Group type: COMPARATOR
Intervention: Surgical curettage
Number of subjects: 80
Study 11763977 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 80
Study 11763977 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol and Surgical curettage
Number of subjects: 80
Study 9313755 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of fasting and 2-h postchallenge insulin levels, fasting triglyceride and HDL cholesterol levels, BMI, and waist-to-hip ratio.
Number of subjects: 2458
Study 9313755 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of fasting and 2-h levels of glucose and insulin.
Number of subjects: 2458
Study 9313755 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of systolic blood pressure, diastolic blood pressure, and BMI.
Number of subjects: 2458
Study 7963427 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms)
Number of subjects: 22
Study 7963427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3316152 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 200 mg bid
Number of subjects: 127
Study 3316152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 31119822 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy (CFT)
Number of subjects: 87
Study 28889225 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR, cuff pressure 20 mmHG below individual occlusion pressure)
Number of subjects: 20
Study 28889225 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR)
Number of subjects: 20
Study 27173030 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced cardiac index (CI)
Number of subjects: 575
Study 24155069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (random acupuncture group, 24 cases)
Number of subjects: 63
Study 24155069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (non-random acupuncture group, 19 cases)
Number of subjects: 63
Study 24155069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined acupuncture group (43 cases)
Number of subjects: 63
Study 24155069 — intervention group
Group type: COMPARATOR
Intervention: Guided rehabilitation (guided rehabilitation group, 24 cases)
Number of subjects: 63
Study 22701334 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exercises using a facilitating device with a compression sleeve
Number of subjects: 20
Study 22701334 — intervention group
Group type: COMPARATOR
Intervention: Active exercises using a facilitating device without a compression sleeve
Number of subjects: 20
Study 20976768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine (10mg twice daily)
Number of subjects: 239
Study 20976768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 18415896 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic pouch anastomosis
Number of subjects: 0
Study 18415896 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J pouch (6-cm length)
Number of subjects: 0
Study 18415896 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloplasty
Number of subjects: 0
Study 18415896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileocecal pouch
Number of subjects: 0
Study 18415896 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse double stapling technique
Number of subjects: 0
Study 18415896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing mesorectal excision
Number of subjects: 0
Study 16841342 — intervention group
Group type: EXPERIMENTAL
Intervention: Short PTSD Rating Interview (SPRINT)
Number of subjects: 0
Study 16841342 — intervention group
Group type: COMPARATOR
Intervention: Clinician‐Administered PTSD Scale for DSM‐IV (CAPS)
Number of subjects: 0
Study 12515870 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-sulesomab
Number of subjects: 7
Study 12515870 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-HSA
Number of subjects: 7
Study 12515870 — intervention group
Group type: COMPARATOR
Intervention: (111)In-leukocytes
Number of subjects: 7
Study 10332907 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Safety in Recovery group (N=48), met three times weekly for one hour
Number of subjects: 86
Study 10332907 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (N=38)
Number of subjects: 86
Study 7673041 — intervention group
Group type: EXPERIMENTAL
Intervention: Five fractions per week
Number of subjects: 1345
Study 7673041 — intervention group
Group type: COMPARATOR
Intervention: Three fractions per week
Number of subjects: 1345
Study 7673041 — intervention group
Group type: EXPERIMENTAL
Intervention: Short overall time (<= 4 weeks)
Number of subjects: 1345
Study 7673041 — intervention group
Group type: COMPARATOR
Intervention: Long overall time (4-7 weeks)
Number of subjects: 1345
Study 7673041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normal-tissue effects
Number of subjects: 1345
Study 7673041 — intervention group
Group type: EXPERIMENTAL
Intervention: Late complications
Number of subjects: 1345
Study 2767906 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention
Number of subjects: 150
Study 2767906 — intervention group
Group type: EXPERIMENTAL
Intervention: Written material intervention
Number of subjects: 150
Study 2767906 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 150
Study 1097344 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-amino-isobutyl-benzol as polysterol-sulfonate
Number of subjects: 16
Study 1097344 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 30547267 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-neutral solutions
Number of subjects: 127
Study 30547267 — intervention group
Group type: COMPARATOR
Intervention: Conventional solutions
Number of subjects: 127
Study 28384480 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Tyrosine administration
Number of subjects: 0
Study 28384480 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tDCS over DLPFC with L-Tyrosine
Number of subjects: 0
Study 25738670 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-CAP (R-CHOP regimen with bortezomib at a dose of 1.3 mg/m² on days 1, 4, 8, and 11)
Number of subjects: 487
Study 25738670 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 487
Study 25738670 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-CAP
Number of subjects: 487
Study 25738670 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 487
Study 23921656 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice gargle (Extractum Liquiritiae Fluidum, 0.5 g in 30 mL water)
Number of subjects: 236
Study 23921656 — intervention group
Group type: COMPARATOR
Intervention: Sugar-water gargle (Sirupus Simplex, 5 g in 30 mL water)
Number of subjects: 236
Study 20673585 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF) as an adjunct to de novo AML remission induction therapy
Number of subjects: 0
Study 20673585 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF)
Number of subjects: 0
Study 20673585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G‐CSF)
Number of subjects: 0
Study 20673585 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 0
Study 20673585 — intervention group
Group type: EXPERIMENTAL
Intervention: Single induction cycle
Number of subjects: 0
Study 19463464 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 146
Study 19463464 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 146
Study 17716311 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-mouth design studies
Number of subjects: 34
Study 17716311 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods used in studies
Number of subjects: 34
Study 17716311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size calculation
Number of subjects: 34
Study 17716311 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis
Number of subjects: 34
Study 15086539 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (0.4‐0.8 mg per day) for 6 weeks
Number of subjects: 21
Study 15086539 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 21
Study 15086539 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol treatment
Number of subjects: 21
Study 15086539 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n=11)
Number of subjects: 21
Study 11473954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT (2 mg oestradiol on days 1‐‐12, 2 mg oestradiol plus 1 mg norethisterone acetate (NETA) on days 13‐‐22, and 1 mg oestradiol on days 23‐‐28, n = 19)
Number of subjects: 38
Study 11473954 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT (50 microg/day of oestradiol on days 1‐‐13, and 50 microg oestradiol plus 250 microg/day NETA on days 14‐‐28, n = 19)
Number of subjects: 38
Study 9777880 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education program
Number of subjects: 0
Study 9777880 — intervention group
Group type: COMPARATOR
Intervention: AGKQA
Number of subjects: 0
Study 8052367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent administration of 0.75 microgram calcitriol twice weekly (total weekly dose of 5.25 micrograms)
Number of subjects: 45
Study 8052367 — intervention group
Group type: COMPARATOR
Intervention: Continuous administration of 0.75 microgram calcitriol daily (total weekly dose of 5.25 micrograms)
Number of subjects: 45
Study 3524067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 0
Study 3524067 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 0
Study 31831276 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 25
Study 31831276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 25
Study 29205158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic total occlusion (CTO) in a non-infarct-related artery
Number of subjects: 761
Study 27528049 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led community-based self-management programme plus usual care
Number of subjects: 160
Study 27528049 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 23839004 — intervention group
Group type: EXPERIMENTAL
Intervention: 21G micropuncture needle
Number of subjects: 100
Study 23839004 — intervention group
Group type: COMPARATOR
Intervention: 19G access needle
Number of subjects: 100
Study 22879899 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART)
Number of subjects: 166
Study 20688442 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg 17β-oestradiol/2.5 mg dydrogesterone (E 0.5 mg/D 2.5 mg)
Number of subjects: 313
Study 20688442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 20688442 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17β-oestradiol/5 mg dydrogesterone (E 1mg/D 5 mg)
Number of subjects: 313
Study 20688442 — intervention group
Group type: EXPERIMENTAL
Intervention: E 0.5 mg/D 2.5 mg
Number of subjects: 313
Study 18950303 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 153
Study 15196155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin (2 MU x 2 times daily)
Number of subjects: 112